Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA). (Q43845709)

27 November 2017

title

Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA). (English)

1 reference

27 November 2017

main subject

carbapenem antibiotic

0 references

2

R N Jones

1 reference

27 November 2017

1

M A Pfaller

1 reference

27 November 2017

D J Biedenbach

3

1 reference

27 November 2017

MYSTIC Program Study Group

series ordinal

4

1 reference

27 November 2017

publication date

1 December 2001

1 reference

Diagnostic Microbiology and Infectious Disease

27 November 2017

published in

1 reference

27 November 2017

volume

41

1 reference

27 November 2017

issue

4

1 reference

27 November 2017

page(s)

177-182

1 reference

Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900319-4

7 January 2021

Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the foss of an outer membrane protein.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900319-4

7 January 2021

Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America. SENTRY Participants Group

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900319-4

7 January 2021

Carbapenem-resistant Serratia marcescens isolates producing Bush group 2f beta-lactamase (SME-1) in the United States: results from the MYSTIC Programme

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900319-4

7 January 2021

MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from Europe: comparison of antibiotic susceptibilities between countries and centre types. MYSTIC Study Group (European centres only).

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900319-4

7 January 2021

MYSTIC program: summary of European data from 1997 to 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900319-4

7 January 2021

The emergent needs for basic research, education, and surveillance of antimicrobial resistance. Problems facing the report from the American Society for Microbiology Task Force on Antibiotic Resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900319-4

7 January 2021

Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900319-4

7 January 2021

Detection of emerging resistance patterns within longitudinal surveillance systems: data sensitivity and microbial susceptibility.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900319-4

7 January 2021

Bacterial resistance: a worldwide problem

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900319-4

7 January 2021

Surveillance studies: how can they help the management of infection?

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900319-4

7 January 2021

Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900319-4

7 January 2021

Antibiotic-resistant bugs: when, where, and why?

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900319-4

7 January 2021

Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900319-4

7 January 2021

Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997).

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900319-4

7 January 2021

MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. MYSTIC Study Group (Americas)

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900319-4

7 January 2021

Integration of molecular characterization of microorganisms in a global antimicrobial resistance surveillance program.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900319-4

7 January 2021

Antimicrobial susceptibility of bacteria causing urinary tract infections in Latin American hospitals: results from the SENTRY Antimicrobial Surveillance Program (1997).

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900319-4

7 January 2021

MYSTIC (Meropenem Yearly Susceptibility Test Information Collection): a global overview

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900319-4

7 January 2021

Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900319-4

7 January 2021

10.1016/S0732-8893(01)00319-4

Identifiers

DOI

1 reference

27 November 2017

1 reference